Image via Wikipedia
First and foremost, the new international guidelines on stem cells, with four Italians among the authors, need to be clear, eliminating false illusions, incredible exaggerations, and confusion due to excess emphasis placed on the therapeutic properties of adult stem cells compared to embryonic stem cells.
The International Society for Stem Cell Research (ISSCR) has decided to impart some order in a field of research which, for various reasons, is growingly involved in issues that have little to do with research.
“Regulation is necessary,” according to the Society, commenting about studies that risk creating exaggerated controversy or omitting risks regarding
Vet-Stem Inc. announced that over 8000 animals have now been treated with Vet-Stem cell therapy.
Vet-Stem began providing stem cells to veterinarians in 2004 and has now provided stem cells for the treatment of over 8,000 animals. Vet-Stem was the first company to introduce rapid turnaround stem cell services in the US.
After providing stem cells for thousands of horses, Vet-Stem pioneered stem cell therapy in dogs and cats and is now the world leader in Regenerative Veterinary Medicine. The rapid adoption of stem cell therapy by equine veterinarians and horse owners provided a springboard for use in small animal veterinary
Image via Wikipedia
A study published this week reinforces the potential value of stem cells in repairing major injuries involving the loss of bone structure.
The study shows that delivering stem cells on a polymer scaffold to treat large areas of missing bone leads to improved bone formation and better mechanical properties compared to treatment with the scaffold alone. This type of therapeutic treatment could be a potential alternative to bone grafting operations.
“Massive bone injuries are among the most challenging problems that orthopedic surgeons face, and they are commonly seen as a result of accidents as well as in soldiers returning
In the first human study of its kind, researchers found that using stem cells to re-grow craniofacial tissues—mainly bone—proved quicker, more effective and less invasive than traditional bone regeneration treatments.
Researchers from the University of Michigan School of Dentistry and the Michigan Center for Oral Health Research partnered with Ann Arbor-based Aastrom Biosciences Inc. in the clinical trial, which involved 24 patients who required jawbone reconstruction after tooth removal.
Patients either received experimental tissue repair cells or traditional guided bone regeneration therapy. The tissue repair cells, called ixmyelocel-T, are under development at Aastrom, which is a U-M spinout company.
Line is first from U-M accepted to the U.S. National Institutes of Health registry, now available for federally-funded research
The University of Michigan’s first human embryonic stem cell line will be placed on the U.S. National Institutes of Health’s registry, making the cells available for federally-funded research. It is the first of the stem cell lines derived at the University of Michigan to be placed on the registry.
The line, known as UM4-6, is a genetically normal line, derived in October 2010 from a cluster of about 30 cells removed from a donated five-day-old embryo roughly the size of the period